Sanofi nabs FDA approval for Kynamro, despite safety concerns

The FDA came through with an approval for Kynamro, a treatment for a rare form of high cholesterol from Sanofi's ($SNY) Genzyme unit. But the agency's blessing came with some strings attached: Four post-marketing studies and long-term safety tracking. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.